.png)
Leukemia Therapeutics Market by Type of Leukemia and Treatment Type - Global Industry Analysis & Forecast to 2027
Published On : August 2019 Pages : 164 Category: Pharma & Healthcare Report Code : HC084847
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Leukemia Therapeutics Market By Type of Leukemia (Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia) and Treatment Type (Targeted Drugs & Immunotherapy and Chemotherapy) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Leukemia is a sort of malignant growth which is framed in blood tissues. Leukemia happens in bone marrow which is a delicate tissue. Leukemia creates by the uncontrolled development of platelets in the bone marrow. Leukemia is additionally characterized as a malignancy of white platelets. White platelets keep from different diseases. Leukemia might be intense or ceaseless and it likewise influences red platelets and platelets. A portion of the normal indications of leukemia incorporate fever, night sweats, weight reduction, amplified liver, visit diseases and swollen lymph hubs.
Drivers and Restraints
In late time there is expanded utilization of leukemia remedial because of rising number of malignant growth infections over the world. Rising maturing populace, way of life factors and expanding mindfulness for human services are a portion of the key driving elements for the development of the worldwide leukemia therapeutics showcase. Furthermore, inventive and focused on medication conveyance is likewise fueling the development of the worldwide leukemia therapeutics advertise. Be that as it may, accessibility of enormous quantities of conventional type of medications and restricted treatment choices are a portion of the main considerations limiting the development of the worldwide leukemia therapeutics market.
Regional Insights
North America followed by Europe dominates the global leukemia therapeutics market due to rising incidence of cancer and growing aging population.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Genzyme Corporation
- Pfizer Inc.
- Celgene Corporation
- Ariad Pharmaceuticals Inc.
- Novartis International AG
- Roche Holding AG
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Leukemia Therapeutics Market, By Type of Leukemia, Estimates and Forecast, 2017-2027 ($Million)
o Chronic Myeloid Leukemia
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Acute Myeloid Leukemia
· Leukemia Therapeutics Market, By Treatment Type, Estimates and Forecast, 2017-2027 ($Million)
o Targeted Drugs & Immunotherapy
o Chemotherapy
· Leukemia Therapeutics Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Genzyme Corporation
o Pfizer Inc.
o Celgene Corporation
o Ariad Pharmaceuticals Inc.
o Novartis International AG
o Roche Holding AG
· Leukemia Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Leukemia Therapeutics Market, By Country
o U.S. Leukemia Therapeutics Market
o Canada Leukemia Therapeutics Market
o Mexico Leukemia Therapeutics Market
o Europe
§ Europe Leukemia Therapeutics Market, By Country
· Germany Leukemia Therapeutics Market
o UK Leukemia Therapeutics Market
o France Leukemia Therapeutics Market
o Russia Leukemia Therapeutics Market
o Italy Leukemia Therapeutics Market
o Rest of Europe Leukemia Therapeutics Market
o Asia-Pacific
§ Asia-Pacific Leukemia Therapeutics Market, By Country
o China Leukemia Therapeutics Market
o Japan Leukemia Therapeutics Market
o South Korea Leukemia Therapeutics Market
o India Leukemia Therapeutics Market
o Southeast Asia Leukemia Therapeutics Market
o Rest of Asia-Pacific Leukemia Therapeutics Market
o South America
§ South America Leukemia Therapeutics Market
o Brazil Leukemia Therapeutics Market
o Argentina Leukemia Therapeutics Market
o Columbia Leukemia Therapeutics Market
o Rest of South America Leukemia Therapeutics Market
o Middle East and Africa
§ Middle East and Africa Leukemia Therapeutics Market
o Saudi Arabia Leukemia Therapeutics Market
o UAE Leukemia Therapeutics Market
o Egypt Leukemia Therapeutics Market
o Nigeria Leukemia Therapeutics Market
o South Africa Leukemia Therapeutics Market
o Rest of MEA Leukemia Therapeutics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Leukemia Therapeutics Market, By Type Of Leukemia
5.1. Introduction
5.2. Global Leukemia Therapeutics Revenue and Market Share by Type Of Leukemia (2017-2027)
5.2.1. Global Leukemia Therapeutics Revenue and Revenue Share by Type Of Leukemia (2017-2027)
5.3. Chronic Myeloid Leukemia
5.3.1. Global Chronic Myeloid Leukemia Revenue and Growth Rate (2017-2027)
5.4. Acute Lymphocytic Leukemia
5.4.1. Global Acute Lymphocytic Leukemia Revenue and Growth Rate (2017-2027)
5.5. Chronic Lymphocytic Leukemia
5.5.1. Global Chronic Lymphocytic Leukemia Revenue and Growth Rate (2017-2027)
5.6. Acute Myeloid Leukemia
5.6.1. Global Acute Myeloid Leukemia Revenue and Growth Rate (2017-2027)
6. Leukemia Therapeutics Market, By Treatment Type
6.1. Introduction
6.2. Global Leukemia Therapeutics Revenue and Market Share by Treatment Type (2017-2027)
6.2.1. Global Leukemia Therapeutics Revenue and Revenue Share by Treatment Type (2017-2027)
6.3. Targeted Drugs & Immunotherapy
6.3.1. Global Targeted Drugs & Immunotherapy Revenue and Growth Rate (2017-2027)
6.4. Chemotherapy
6.4.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
7. Leukemia Therapeutics Market, By Region
7.1. Introduction
7.2. Global Leukemia Therapeutics Revenue and Market Share by Regions
7.2.1. Global Leukemia Therapeutics Revenue by Regions (2017-2027)
7.3. North America Leukemia Therapeutics by Countries
7.3.1. North America Leukemia Therapeutics Revenue and Growth Rate (2017-2027)
7.3.2. North America Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Leukemia Therapeutics by Countries
7.4.1. Europe Leukemia Therapeutics Revenue and Growth Rate (2017-2027)
7.4.2. Europe Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Leukemia Therapeutics by Countries
7.5.1. Asia-Pacific Leukemia Therapeutics Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Leukemia Therapeutics by Countries
7.6.1. South America Leukemia Therapeutics Revenue and Growth Rate (2017-2027)
7.6.2. South America Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Leukemia Therapeutics by Countries
7.7.1. Middle East and Africa Leukemia Therapeutics Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Genzyme Corporation
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Pfizer Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Celgene Corporation
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Ariad Pharmaceuticals Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Novartis International AG
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Roche Holding AG
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
9. Leukemia Therapeutics Market Forecast (2017-2027)
9.1. Global Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Leukemia Therapeutics Market Forecast by Regions (2017-2027)
9.2.1. North America Leukemia Therapeutics Market Forecast (2017-2027)
9.2.1.1. United States Leukemia Therapeutics Market Forecast (2017-2027)
9.2.1.2. Canada Leukemia Therapeutics Market Forecast (2017-2027)
9.2.1.3. Mexico Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2. Europe Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2.1. Germany Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2.2. France Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2.3. UK Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2.4. Russia Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2.5. Italy Leukemia Therapeutics Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3. Asia-Pacific Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3.1. China Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3.2. Japan Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3.3. Korea Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3.4. India Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Leukemia Therapeutics Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Leukemia Therapeutics Market Forecast (2017-2027)
9.2.4. South America Leukemia Therapeutics Market Forecast (2017-2027)
9.2.4.1. Brazil Leukemia Therapeutics Market Forecast (2017-2027)
9.2.4.2. Argentina Leukemia Therapeutics Market Forecast (2017-2027)
9.2.4.3. Columbia Leukemia Therapeutics Market Forecast (2017-2027)
9.2.4.4. Rest of South America Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5. Middle East and Africa Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.3. Egypt Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.4. Nigeria Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.5. South Africa Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.6. Turkey Leukemia Therapeutics Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Leukemia Therapeutics Market Forecast (2017-2027)
9.3. Leukemia Therapeutics Market Forecast by Type Of Leukemia (2017-2027)
9.3.1. Leukemia Therapeutics Forecast by Type Of Leukemia (2017-2027)
9.3.2. Leukemia Therapeutics Market Share Forecast by Type Of Leukemia (2017-2027)
9.4. Leukemia Therapeutics Market Forecast by Treatment Type (2017-2027)
9.4.1. Leukemia Therapeutics Forecast by Treatment Type (2017-2027)
9.4.2. Leukemia Therapeutics Market Share Forecast by Treatment Type (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Leukemia Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Leukemia Therapeutics Revenue and Revenue Share by Type Of Leukemia (2017-2018)
Figure Global Chronic Myeloid Leukemia Revenue and Growth Rate (2017-2018)
Figure Global Acute Lymphocytic Leukemia Revenue and Growth Rate (2017-2018)
Figure Global Chronic Lymphocytic Leukemia Revenue and Growth Rate (2017-2018)
Figure Global Acute Myeloid Leukemia Revenue and Growth Rate (2017-2018)
Table Global Leukemia Therapeutics Revenue and Revenue Share by Treatment Type (2017-2018)
Figure Global Targeted Drugs & Immunotherapy Revenue and Growth Rate (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Table Global Leukemia Therapeutics Revenue by Regions (2017-2018)
Figure North America Leukemia Therapeutics Growth Rate (2017-2018)
Figure North America Leukemia Therapeutics Revenue and Growth Rate (2017-2018)
Figure North America Leukemia Therapeutics by Countries (2017-2018)
Figure North America Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure United States Leukemia Therapeutics Growth Rate (2017-2018)
Figure United States Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Leukemia Therapeutics Growth Rate (2017-2018)
Figure Canada Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Leukemia Therapeutics Growth Rate (2017-2018)
Figure Mexico Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Leukemia Therapeutics Growth Rate (2017-2018)
Figure Europe Leukemia Therapeutics Revenue and Growth Rate (2017-2018)
Figure Europe Leukemia Therapeutics by Countries (2017-2018)
Figure Europe Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Leukemia Therapeutics Growth Rate (2017-2018)
Figure Germany Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Leukemia Therapeutics Growth Rate (2017-2018)
Figure France Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Leukemia Therapeutics Growth Rate (2017-2018)
Figure UK Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Leukemia Therapeutics Growth Rate (2017-2018)
Figure Russia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Leukemia Therapeutics Growth Rate (2017-2018)
Figure Italy Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Leukemia Therapeutics Growth Rate (2017-2018)
Figure Rest of Europe Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Leukemia Therapeutics Growth Rate (2017-2018)
Figure Asia-Pacific Leukemia Therapeutics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Leukemia Therapeutics by Countries (2017-2018)
Figure Asia-Pacific Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure China Leukemia Therapeutics Growth Rate (2017-2018)
Figure China Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Leukemia Therapeutics Growth Rate (2017-2018)
Figure Japan Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Leukemia Therapeutics Growth Rate (2017-2018)
Figure Korea Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Leukemia Therapeutics Growth Rate (2017-2018)
Figure India Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Leukemia Therapeutics Growth Rate (2017-2018)
Figure Southeast Asia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Leukemia Therapeutics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Leukemia Therapeutics Growth Rate (2017-2018)
Figure South America Leukemia Therapeutics Revenue and Growth Rate (2017-2018)
Figure South America Leukemia Therapeutics by Countries (2017-2018)
Figure South America Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Leukemia Therapeutics Growth Rate (2017-2018)
Figure Brazil Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Leukemia Therapeutics Growth Rate (2017-2018)
Figure Argentina Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Leukemia Therapeutics Growth Rate (2017-2018)
Figure Columbia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Leukemia Therapeutics Growth Rate (2017-2018)
Figure Rest of South America Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Leukemia Therapeutics Growth Rate (2017-2018)
Figure Middle East and Africa Leukemia Therapeutics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Leukemia Therapeutics by Countries (2017-2018)
Figure Middle East and Africa Leukemia Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Leukemia Therapeutics Growth Rate (2017-2018)
Figure Saudi Arabia Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Leukemia Therapeutics Growth Rate (2017-2018)
Figure United Arab Emirates Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Leukemia Therapeutics Growth Rate (2017-2018)
Figure Egypt Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Leukemia Therapeutics Growth Rate (2017-2018)
Figure Nigeria Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Leukemia Therapeutics Growth Rate (2017-2018)
Figure South Africa Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Leukemia Therapeutics Growth Rate (2017-2018)
Figure Turkey Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Leukemia Therapeutics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Genzyme Corporation Leukemia Therapeutics Financial Overview
Table Pfizer Inc. Leukemia Therapeutics Financial Overview
Table Celgene Corporation Leukemia Therapeutics Financial Overview
Table Ariad Pharmaceuticals Inc. Leukemia Therapeutics Financial Overview
Table Novartis International AG Leukemia Therapeutics Financial Overview
Table Roche Holding AG Leukemia Therapeutics Financial Overview
Figure Global Leukemia Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Leukemia Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Leukemia Therapeutics Market Forecast (2018-2025)
Figure United States Leukemia Therapeutics Market Forecast (2018-2025)
Figure Canada Leukemia Therapeutics Market Forecast (2018-2025)
Figure Mexico Leukemia Therapeutics Market Forecast (2018-2025)
Figure Europe Leukemia Therapeutics Market Forecast (2018-2025)
Figure Germany Leukemia Therapeutics Market Forecast (2018-2025)
Figure France Leukemia Therapeutics Market Forecast (2018-2025)
Figure UK Leukemia Therapeutics Market Forecast (2018-2025)
Figure Russia Leukemia Therapeutics Market Forecast (2018-2025)
Figure Italy Leukemia Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Leukemia Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Leukemia Therapeutics Market Forecast (2018-2025)
Figure China Leukemia Therapeutics Market Forecast (2018-2025)
Figure Japan Leukemia Therapeutics Market Forecast (2018-2025)
Figure Korea Leukemia Therapeutics Market Forecast (2018-2025)
Figure India Leukemia Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Leukemia Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Leukemia Therapeutics Market Forecast (2018-2025)
Figure South America Leukemia Therapeutics Market Forecast (2018-2025)
Figure Brazil Leukemia Therapeutics Market Forecast (2018-2025)
Figure Argentina Leukemia Therapeutics Market Forecast (2018-2025)
Figure Columbia Leukemia Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Leukemia Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Leukemia Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Leukemia Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Leukemia Therapeutics Market Forecast (2018-2025)
Figure Egypt Leukemia Therapeutics Market Forecast (2018-2025)
Figure Nigeria Leukemia Therapeutics Market Forecast (2018-2025)
Figure South Africa Leukemia Therapeutics Market Forecast (2018-2025)
Figure Turkey Leukemia Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Leukemia Therapeutics Market Forecast (2018-2025)
Figure Global Leukemia Therapeutics Forecast by Type Of Leukemia (2018-2025)
Figure Global Leukemia Therapeutics Market Share Forecast by Type Of Leukemia (2018-2025)
Figure Global Leukemia Therapeutics Forecast by Type Of Leukemia (2018-2025)
Figure Global Leukemia Therapeutics Forecast by Treatment Type (2018-2025)
Figure Global Leukemia Therapeutics Market Share Forecast by Treatment Type (2018-2025)
Figure Global Leukemia Therapeutics Forecast by Treatment Type (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|